Sino Biopharmaceutical is a leading pharmaceutical conglomerate in China, specializing in biopharmaceutical and chemical medicines. Listed on the Hong Kong Stock Exchange since 2000, it became a constituent of the MSCI Global Standard Indices – MSCI China Index in 2013, the Hang Seng Index in 2018, the Hang Seng China Enterprises Index in 2019, and the Hang Seng Connect Biotech 50 Index and the Hang Seng China (Hong Kong-listed) 25 Index in 2020. Its portfolio spans therapeutic areas such as oncology, liver diseases, respiratory system diseases and surgery/analgesia. It has manufacturing sites in Beijing, Shanghai, Nanjing, Lianyungang, Qingdao and other key locations.